Citalopram Stada

Quick links

Choose a section

Quick links to important sections

Advertisements
Advertisements

Overview of Citalopram Stada

Citalopram Stada is a foundational medication defined by its precise chemical composition and pharmacological activity. It is a prescription-only product with the active ingredient Escitalopram, manufactured by STADA Arzneimittel AG.

Property Description
Active ingredient Escitalopram (as Escitalopram oxalate)
Form Film-coated tablets, Oral solution
Pharmacological class Selective Serotonin Reuptake Inhibitor (SSRI)
Common use Modulating mood and emotional balance
Origin Synthetic, single-isomer derivative

What Type of Medicine is Citalopram Stada?

Citalopram Stada is classified as a synthetic prescription-only agent belonging to the pharmacological class known as a Selective Serotonin Reuptake Inhibitor (SSRI). This classification is based on Escitalopram's high affinity for the serotonin reuptake mechanism. The general therapeutic application of this drug class is to assist in modulating emotional states, thereby promoting the stability of mood and mental well-being.

How is Escitalopram Composed and Supplied?

The active ingredient is Escitalopram, typically supplied as the oxalate salt, Escitalopram oxalate. The medication is prepared for oral administration and is offered in pharmaceutical forms such as film-coated tablets and an oral solution. A critical element of its composition is its origin as a single-isomer derivative, meaning it is purified to consist exclusively of the S-enantiomer, the specific molecular form responsible for the therapeutic effect.

Why Does the Single-Isomer Composition Matter?

The defining characteristic of Escitalopram is its molecular refinement: it contains only the active S-enantiomer, unlike its precursor, racemic citalopram, which contains both active and less active mirror-image molecular forms. The S-enantiomer is significantly more potent in inhibiting serotonin reuptake compared to the R-enantiomer found in the older compound. This single-isomer design is a scientifically informed choice intended to ensure the most efficient and targeted engagement with the Serotonin Transporter (SERT), which is the fundamental action necessary to help stabilize neural communication.

Regulatory References

  1. Escitalopram SmPC (emc)
  2. EMA Escitalopram PSUSA Overview
  3. NIH Escitalopram StatPearls Review
Advertisements

What side effects are possible with Citalopram Stada?

Possible side effects and safety information

The safety profile of Citalopram Stada is defined by adverse reactions classified according to official regulatory standards (e.g., EMA/FDA). These reactions are typically categorized by frequency and the physiological systems affected, providing a structured overview of potential effects.

Category Official Regulatory Statement
Frequency classification Very Common (ge 10% incidence) adverse reactions officially listed are Nausea and Headache. Common (1% to 10% incidence) effects include Insomnia, Somnolence, Diarrhea, Dry mouth, Increased sweating, and Ejaculatory disorder.
System-organ classes involved Adverse effects are grouped into categories such as Gastrointestinal disorders (e.g., nausea), Nervous system disorders (e.g., headache, tremor), Psychiatric disorders (e.g., anxiety, decreased libido), and Reproductive system and breast disorders.

The official label also documents safety concerns that require specific attention. These include the risk of Serotonin Syndrome, QT-interval prolongation (a change in the heart's electrical activity), seizures, hyponatremia (low sodium levels), and the activation of mania/hypomania. The risk of suicidal thoughts and behaviors is officially noted to be highest early in treatment or following dose changes.

Specific contraindications limit use, including patients with a known prolongation of the QT interval or those taking non-selective irreversible Monoamine Oxidase Inhibitors (MAOIs). Safety statements exist for special groups; for example, older adults have an increased susceptibility to hyponatremia and bleeding events, and use in the pediatric population (under 18) is generally not recommended due to safety observations for this drug class.

Advertisements

Overdose and Emergency Response

Overdose and When to Seek Help

Immediate medical attention is required in all cases of suspected overdose. The severity of citalopram overdose is often dose-dependent, with severe, life-threatening effects primarily associated with very high-dose ingestions, particularly those above 600 mg in adults, or co-ingestion with other serotonergic or QT-prolonging agents.

Documented Overdose Manifestations

Citalopram overdose is primarily associated with both cardiac and neurological toxicities. Clinical manifestations may be mild to severe and typically involve:

  • Cardiovascular System: QT interval prolongation (a heart rhythm abnormality), Torsade de Pointes (a severe, life-threatening arrhythmia), ventricular arrhythmias, tachycardia (rapid heart rate), bradycardia (slow heart rate), and hypotension (low blood pressure).
  • Central Nervous System: Serotonin syndrome, which can present as agitation, hallucinations, confusion, coma, seizures, severe muscle rigidity, and hyperthermia (high body temperature). Other effects include somnolence, tremor, and myoclonus (muscle twitching).

When to Seek Emergency Medical Help

Urgent medical evaluation is necessary if any of the following signs or symptoms occur:

  • Irregular or rapid heartbeat, dizziness, or fainting (syncope).
  • Seizures or convulsions.
  • Sudden high fever, profuse sweating, extreme agitation, or severe muscle stiffness, which may indicate Serotonin Syndrome.
  • Difficulty breathing or loss of consciousness.

Overdose risk is heightened in individuals with pre-existing heart conditions, congenital long QT syndrome, uncompensated heart failure, or imbalances of electrolytes like hypokalemia or hypomagnesemia. Treatment of overdose is supportive and symptomatic, and continuous cardiac monitoring is often required, particularly with large ingestions. Do not wait for symptoms to worsen; contact emergency services immediately.

Advertisements

Therapeutic Uses of Citalopram Stada

Quick Facts: Citalopram Stada

Primary Use Associated Benefit Domains
Major Depressive Disorder (MDD) Supports emotional well-being
Assists in managing low mood

What Citalopram Stada is Used to Address

Citalopram is a widely used prescription medication authorized to support individuals managing Major Depressive Disorder (MDD), commonly referred to as clinical depression, in adults. It functions as a pharmacological resource intended to help modulate the core symptoms of the condition.

In clinical practice, this medication may be considered part of a therapeutic plan to assist with persistent feelings of low mood, loss of interest or pleasure, and other features associated with a depressive episode.

Therapeutic Domains and Benefits

Using Citalopram Stada, in conjunction with guidance from a healthcare professional, offers support in several key therapeutic domains:

  • Promoting Emotional Well-being: It is an agent that helps to stabilize mood and supports the maintenance of a balanced emotional state.
  • Assisting Symptom Management: The treatment is indicated to help control the presence and intensity of depressive symptoms over time, facilitating an improved level of function in daily life.

The primary purpose of Citalopram is the management of the symptoms of depression, serving as a support tool for many adults seeking relief from their condition. Additionally, a healthcare provider may determine that this medication is a suitable part of a management strategy for other related conditions, based on current clinical understanding.

Advertisements

Eligibility and Restrictions for Use

Who Can and Cannot Use Citalopram Stada?

Citalopram Stada (Escitalopram) eligibility is strictly defined by regulatory authorities based on population characteristics and existing health conditions. This medication is primarily approved for use in adults for conditions like Major Depressive Disorder (MDD). In some jurisdictions, it is approved for adolescents 12 to 17 years for MDD, though it is generally not recommended for children under 18 in others.

Absolute Contraindications

Use is contraindicated (absolutely forbidden) in the following patient groups:

  • Patients with documented hypersensitivity to escitalopram, citalopram, or any component of the formulation.
  • Patients using or having recently used (within 14 days) a Monoamine Oxidase Inhibitor (MAOI), including linezolid.
  • Patients with known QT-interval prolongation or those using other medications known to prolong the QT-interval.

Conditional Use and Restrictions

Special consideration is required for several populations:

  • Older Adults (Geriatric): A lower maximum daily dose is recommended.
  • Hepatic Impairment: Patients with liver impairment require a reduced maximum daily dose.
  • Severe Renal Impairment: The medicine should be used with caution.
  • Pregnancy and Lactation: Use is generally advised only if the potential benefit justifies the potential risk to the fetus or infant, and caution is exercised in nursing mothers.
Advertisements

What should I know about interactions with other medicines?

Official Interaction Restrictions

The regulatory profile for Citalopram Stada is structured by specific prohibitions and required cautions. The co-administration with Monoamine Oxidase Inhibitors (MAOIs), including Linezolid and Moclobemide, is strictly contraindicated due to the high, documented risk of Serotonin Syndrome. Additionally, co-administration with Pimozide is prohibited because it is known to increase the risk of QT interval prolongation. When switching from an irreversible MAOI, a mandatory 14-day washout period is required before starting Citalopram Stada.

Pharmacokinetic and Pharmacodynamic Effects

Citalopram Stada is documented as a weak inhibitor of the CYP2D6 enzyme, which may lead to an increase in the plasma concentration of medicines metabolized by this pathway, such as Metoprolol. Conversely, co-administration with inhibitors of CYP2C19 (e.g., Omeprazole) may increase the exposure of Citalopram Stada itself. Combining Citalopram Stada with other serotonergic agents, including Triptans, Tramadol, or the herbal product St. John's Wort, is officially noted to reinforce the risk of Serotonin Syndrome. Furthermore, co-administration with products that affect hemostasis, such as NSAIDs and Warfarin, increases the documented risk of abnormal bleeding events. Alcohol use is generally advised against due to the potential for additive CNS effects.

Advertisements

Mechanism of Action

Targeting the Serotonin Reuptake Mechanism

Citalopram Stada's primary mechanism involves the highly selective inhibition of the serotonin transporter (SERT), a protein responsible for clearing the neurotransmitter serotonin (5 -HT) from the synaptic cleft. The binding action leads to the immediate elevation of the concentration of serotonin available to interact with postsynaptic receptors, initiating the core pathway modulation that defines the drug's activity.

Modulating Central Serotonergic Pathways

By increasing extracellular serotonin levels, Citalopram Stada engages a cascading mechanism that eventually leads to a downstream adjustment of receptor sensitivity within specific central neural circuits. This initiates a process that alters the dynamics of specific physiological pathways where serotonin plays a dominant role, resulting in the adjustment of neural pathway activity.

High Mechanistic Selectivity

The drug demonstrates very low affinity for other key targets like histamine, dopamine, and adrenergic receptors. This high mechanistic selectivity means the resulting physiological effects are primarily influenced by the modulation of the serotonergic system, resulting in minimal interaction with other regulatory feedback mechanisms, and shaping a specific pattern of physiological adjustment.

Advertisements

Dosage and Administration Information

Official Instructions for Use

Citalopram Stada, which contains the active ingredient Escitalopram, is administered exclusively by the oral route. The dosing instructions define the initial dose, maximum limits, and administration conditions.

Standard Labeled Dosing Regimens

Population Initial Daily Dose Maximum Daily Dose
Adults 10 mg 20 mg
Older Adults (ge65 years) 10 mg 10 mg
Hepatic Impairment N/A 10 mg

Administration Schedule and Conditions

  • Frequency: The medication is administered once daily, either in the morning or the evening.
  • Food Intake: Dosing may occur with or without food.
  • Dosage Forms: It is supplied as film-coated tablets (5 mg, 10 mg, and 20 mg) and as an oral solution (1 mg per mL). The 10 mg and 20 mg tablets are typically scored and can be divided.
  • Titration: Any increase in dosage from the initial 10 mg must occur after a minimum interval of one week.
  • Discontinuation: Treatment cessation should involve a gradual dose reduction (tapering) to minimize the risk of discontinuation symptoms. Abrupt stopping is not recommended.
  • Missed Dose: If a dose is missed, it should be taken as soon as remembered, unless it is almost time for the next scheduled dose, in which case the missed dose should be skipped. Do not double doses to compensate.

These instructions establish the administrative parameters and dose limitations necessary for the standardized use of Escitalopram, particularly for specific populations like the elderly or those with impaired liver function.

Advertisements

Recent Clinical Evidence

Research Evidence / Overview of Studies for Citalopram Stada


Evidence Structure for Major Depressive Disorder (MDD)

Citalopram (Escitalopram) was studied for Major Depressive Disorder, a condition characterized by fluctuating or episodic manifestations. The primary research relied on Randomized Controlled Trials (RCTs), where the medicine was evaluated in adults compared against either an inactive substance (placebo) or another active antidepressant. These short-term trials, typically lasting six to eight weeks, focused on outcomes related to systemic or functional imbalance and the measurement of symptom intensity or variability using established clinical scales.

The research examined how symptoms evolved in the observed populations during the study periods. Findings describe patterns observed in the studies related to changes in overall depressive symptom severity. Studies also monitored the rates at which patients reached a pre-defined threshold for response or remission.

Evidence Structure for Generalized Anxiety Disorder (GAD)

Research was studied for Generalized Anxiety Disorder (GAD), a condition marked by functional limitations and often involving periods of heightened symptoms. The evidence primarily stems from controlled clinical trials that were conducted during periods of increased symptom activity. These studies monitored outcomes reflecting daily functioning or activity level, alongside measures of anxiety symptom severity using specific clinical rating scales.

Data show patterns related to observed changes in anxiety symptom scores and how the symptoms evolved in the observed populations. Research also highlighted changes measured during the study period in functional scales designed to capture patient-reported outcomes describing perceived discomfort and impairment.

Gaps and Limitations in the Research Landscape

Long-term effects are not fully established beyond short-to-intermediate follow-up durations. Comparative evidence is lacking in some areas, meaning direct outcomes against all relevant treatments are not always available. Furthermore, subgroup findings are uncertain or limited for populations such as those with certain comorbidities, indicating that the study results reflect the specific conditions under which they were conducted and not necessarily all patient scenarios.

Key Studies & References

  1. EMA Public Assessment Report Scientific discussion Escitalopram Bristol
Advertisements

Frequently Asked Questions (FAQ)

Common questions about Citalopram Stada (FAQ)


Q: What happens if a person stops taking Citalopram Stada suddenly?

Regulatory documents describe risks associated with abrupt discontinuation of this medication. Stopping suddenly can lead to symptoms sometimes described as a discontinuation syndrome. These effects are officially noted to include dizziness, electric shock sensations, feelings of anxiety, and nausea.


Q: Is it common to experience changes in sleep patterns when starting Citalopram Stada?

According to official product information, changes in sleep are common, meaning they are reported in 1% to 10% of patients in clinical studies. This can manifest as either insomnia (difficulty sleeping) or somnolence (feeling drowsy or sleepy).


Q: Can Citalopram Stada cause or contribute to increased anxiety initially?

Anxiety is described in official reports as a common side effect. Regulatory warnings note that a small number of patients taking this type of medication may experience new or worsened feelings of agitation or anxiety, particularly in the first few weeks of treatment or after a dose adjustment.


Q: What is the difference between Citalopram and Escitalopram?

Citalopram Stada contains Escitalopram, which is the purified form of Citalopram. Escitalopram is described in research as significantly more potent in engaging the serotonin reuptake mechanism than the older compound, Citalopram.


Q: What are the descriptions of Citalopram Stada's mechanism of action?

Citalopram Stada is classified as a Selective Serotonin Reuptake Inhibitor (SSRI). Its mechanism of action involves inhibiting the reuptake of the neurotransmitter serotonin in the brain, which increases the amount of serotonin available. This action is believed to modulate pathways associated with mood and emotional balance.


Q: Can Citalopram Stada cause headaches?

Yes, headache is officially listed as a very common side effect in regulatory documents, meaning it is reported in 10% or more of patients during clinical studies.


Q: Is it normal to feel a change in sexual function while on Citalopram Stada?

Changes in sexual function are common when using this medication. Official product information lists decreased sex drive (libido), difficulty reaching orgasm, and ejaculatory disorder among the common side effects.


Q: What research is available on the long-term safety of Citalopram Stada?

The available regulatory research evidence is primarily based on short-term or intermediate-duration studies. Because of this, the long-term effects of use beyond those follow-up durations are not fully established in the research landscape.


Q: How quickly do people usually start noticing any effects after beginning Citalopram Stada?

Individual responses may vary, but the initial effects on anxiety or mood-related symptoms may begin to be noticeable within the first few weeks of treatment. Full therapeutic effects may generally take longer to develop.


Q: What is the expected timeframe before the full effects of Citalopram Stada may be observed?

Efficacy for its approved uses is typically evaluated in controlled clinical trials that last six to eight weeks. Full benefits related to the regulation of emotional balance may be observed over this period or longer.


Q: Does Citalopram Stada affect weight, causing gain or loss?

Changes in weight are officially documented as a potential side effect. Official patient information notes that both increased weight and weight loss are possible effects.


Q: Can Citalopram Stada cause feelings of tiredness or drowsiness?

Yes, both somnolence (drowsiness) and fatigue (feeling very tired) are officially listed as common side effects. This means they are reported in 1% to 10% of patients in clinical studies.


Q: Are there any specific supplements or vitamins that should be avoided while using Citalopram Stada?

The herbal product St. John's Wort is officially noted to increase the risk of Serotonin Syndrome, and its co-administration is generally restricted. Official guidance states that there is not enough information to confirm the safety of all other herbal remedies when taken with Citalopram Stada.


Q: Is Citalopram Stada considered a controlled substance?

No, Citalopram Stada (Escitalopram) is not classified as a controlled substance by the US Drug Enforcement Administration (DEA) or other regulatory bodies.


Q: Does Citalopram Stada have a potential for dependency?

Citalopram Stada is not classified as a substance with a high potential for abuse. However, long-term use can lead to physical dependence, which means the body has adapted to the medication and may result in discontinuation symptoms if the medicine is stopped suddenly.


Q: Is Citalopram Stada known by any other brand names?

Citalopram Stada contains the active ingredient Escitalopram. Escitalopram is sold under several brand names in various global jurisdictions, including Lexapro and Cipralex.


Q: What is Citalopram Stada's safety classification?

Official regulatory documents include specific statements regarding the use of this medicine during pregnancy and breastfeeding. For example, in Australia, Escitalopram is assigned Pregnancy Category C, which describes drugs that may cause harmful, reversible effects on the fetus or neonate without causing malformations.


Q: Do studies suggest Citalopram Stada is effective for Panic Disorder?

The approved uses may vary by global region. While it is approved for Major Depressive Disorder and Generalized Anxiety Disorder in some areas, in other jurisdictions (such as Europe), Escitalopram is approved for the treatment of Panic Disorder, with or without Agoraphobia.


Q: Why does the packaging for Citalopram Stada include a specific warning about the first few weeks of treatment?

The packaging warnings reflect regulatory requirements to inform patients that the risk of suicidal thoughts and behaviors is noted to be highest early in treatment or following dose changes. The labeling indicates that close observation by a doctor is a necessary precaution during this time.


Q: Can Citalopram Stada be taken indefinitely for long-term support?

Maintenance treatment for conditions like Major Depressive Disorder is generally agreed to require several months or longer of sustained therapy. Official guidelines indicate that the long-term usefulness of the drug should be periodically re-evaluated by the prescriber.


Q: Does Citalopram Stada affect blood pressure?

While not listed as a common side effect in standard use, regulatory documents note that decreased blood pressure is a potential finding. This information is typically found in the context of overdose reports.


Q: Are there specific checks or tests a person needs before starting Citalopram Stada?

Regulatory information indicates that a doctor may perform checks to screen for conditions that are absolute contraindications for use. For example, a doctor may check the heart using an electrocardiogram (ECG) to screen for known QT-interval prolongation, and check for a personal history of mania or hypomania.


Q: Is hair loss described as a possible side effect of Citalopram Stada?

Hair loss (alopecia) is not typically listed in the common side effect tables found in the main product information. However, it is documented in post-marketing or case reports as a possible infrequent adverse reaction.


Q: Does Citalopram Stada have a bitter or unpleasant taste?

Citalopram Stada is supplied as film-coated tablets and an oral solution. While the tablets are not intended to be tasted, the flavor of the oral solution is determined during formulation, though not explicitly detailed in the general regulatory summaries.


Q: Are generic Citalopram products considered therapeutically equivalent to Citalopram Stada?

Yes. Regulatory agencies, such as the FDA, require that generic medicines containing Escitalopram be proven bioequivalent to the brand-name counterpart. This ensures they are the same in dosage, safety, effectiveness, strength, stability, and quality.


Q: Why are people often told to start Citalopram Stada at a low amount?

Regulatory guidance defines a low initial starting dose before any potential dose increase. Starting with a lower dose is a strategy often utilized to potentially minimize the incidence or severity of initial side effects.


Q: Can Citalopram Stada cause changes in appetite?

Changes in appetite are officially noted as a potential side effect of this medication. This can include either loss of appetite or increased appetite.


Q: Is Citalopram Stada appropriate for use in children or adolescents?

Official guidance varies by region. While it is approved for Major Depressive Disorder in adolescents 12 to 17 years old in some jurisdictions, use in the overall pediatric population (under 18) is generally not recommended in others due to safety observations for this drug class.


Q: Why is Citalopram Stada sometimes referred to as 'Celexa'?

Citalopram Stada contains the active ingredient Escitalopram. It is sometimes confused with Citalopram, the racemic precursor, which is the active ingredient in the brand-name drug Celexa. The two are closely related but chemically distinct compounds.

Advertisements

How should Citalopram Stada be stored and disposed of?

Storage and Disposal of Citalopram Tablets

Citalopram tablets must be stored at controlled room temperature, typically 20 C to 25 C (68 F to 77 F), with permitted temperature variations up to 30 C (86 F). The medication must be protected from light, moisture, and excessive heat, and it is required to keep from freezing.

  • Container and Protection: Tablets must be kept in the original container, tightly closed.
  • Child Safety: Store the medicine strictly out of the sight and reach of children.

Official Disposal Rules

To dispose of unused or expired Citalopram, do not throw it into the household trash or flush it down the toilet or drain. Unused product must be discarded in accordance with local requirements or by consulting a healthcare professional about available drug take-back programs.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Citalopram Stada found in:

A-Z Index: